Shares of cannabis companies reversed early gains on April 23, 2026, as investors took a closer look at the limited scope of the U.S. government's move to reclassify marijuana as a less-dangerous drug. The initial rally, driven by optimism over the rescheduling, faded after analysts highlighted that the change only applies to FDA-approved and state-licensed products.
According to a Reuters report from April 23, 2026, the U.S. Drug Enforcement Administration (DEA) proposed reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act. This move, while historic, does not legalize recreational use or affect federal enforcement against unlicensed operators.
Companies like Cronos Group and Aurora Cannabis saw their shares drop after early gains, as the market adjusted to the reality that the rescheduling primarily benefits medical marijuana and research, not the broader industry. The DEA's proposal is subject to a public comment period and final approval.
Analysts noted that the rescheduling could reduce tax burdens for state-licensed businesses under IRS Section 280E, but the overall impact on the sector remains uncertain. The news underscores the cautious approach of investors amid ongoing regulatory complexities.
